Titre : | Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review (2016) |
Auteurs : | J. COPELAND ; I. POKORSKI |
Type de document : | Article : Périodique |
Dans : | Substance Abuse and Rehabilitation (Vol.7, 2016) |
Article en page(s) : | 41-53 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés CANNABIS ; PHARMACOTHERAPIE ; SEVRAGE ; TRAITEMENT ; INTERVENTION ; CANNABINOIDES ; AGONISTE ; ANTAGONISTE |
Résumé : | Cannabis is the most widely used and variably regulated drug in the world, with increasing trends of use being reported in the US, Australia, Asia, and Africa. Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users. Cannabis use is associated with numerous health risks and long-term morbidity, as well as risk of developing cannabis-use disorders. Cannabis users infrequently seek professional treatment, and normally do so after a decade of use. Cannabis-use disorders are currently treated using a selection of psychosocial interventions. Severity of withdrawal is a factor that increases the risk of relapse, and is the target of pharmacotherapy studies. Currently, there is no approved pharmacotherapy for cannabis-use disorders. A number of approaches have been examined, and trials are continuing to find a safe and effective medication with little abuse liability. |
Domaine : | Drogues illicites / Illicit drugs |
Sous-type de document : | Revue de la littérature / Literature review |
Refs biblio. : | 111 |
Affiliation : | UNSW Medicine, University of New South Wales, Sydney, NSW, Australia |
Lien : | https://dx.doi.org/10.2147/SAR.S89857 |
Accueil